Status:
COMPLETED
Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)
Lead Sponsor:
Gilead Sciences
Conditions:
HIV
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study of HIV-1 negative individuals who participated in demonstration projects or clinical studies and took daily Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF, Truvada...
Eligibility Criteria
Inclusion
- Participants in an FTC/TDF for PrEP observational or clinical study
- HIV-1 negative individual at the time of enrollment in a demonstration project or clinical study
- Participants with at least one measurement of tenofovir-diphosphate (TFV-DP) in dried blood spot (DBS) or tenofovir (TFV) in plasma
Exclusion
- This is an observational study and will collect HIV-1 infection and resistance information along with renal or skeletal adverse events without intervention.
Key Trial Info
Start Date :
October 7 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 27 2021
Estimated Enrollment :
10577 Patients enrolled
Trial Details
Trial ID
NCT01906255
Start Date
October 7 2013
End Date
April 27 2021
Last Update
September 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gilead Sciences, Inc.
Foster City, California, United States, 94404